Context Therapeutics Inc. (CNTX) shareholders
Close on Nov 16, 2026Market cap $15.24MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Michael Gregory Joint filing with Avidity Partners Management LP (9.90%), Avidity Partners Management (GP) LLC (9.90%) and 3 more | 9,200,580 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Avidity Capital Partners (GP) LLC Joint filing with Avidity Partners Management LP (8.70%), Avidity Partners Management (GP) LLC (8.70%) and 3 more | 8,302,808 | 8.70% | 13G (passive) amendment | Mar 31, 2026 |
| Avidity Private Master Fund I LP Joint filing with Avidity Partners Management LP (9.90%), Avidity Partners Management (GP) LLC (9.90%) and 4 more | 7,776,296 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Ian Charoub Joint filing with Nextech Crossover I SCSp (9.90%), Nextech Crossover I GP S.à r.l (9.90%) and 2 more | 7,419,355 | 9.90% | 13G (passive) | May 6, 2024 |
| David Kroin Joint filing with Deep Track Capital, LP (8.27%), Deep Track Biotechnology Master Fund, Ltd. (8.27%) | 7,419,355 | 8.27% | 13G (passive) amendment | Mar 31, 2025 |
| Soleus Capital Management, L.P. Joint filing with Soleus Capital Master Fund, L.P. (7.60%), Soleus Capital, LLC (7.60%) and 3 more | 6,963,141 | 7.60% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 6,169,250 | 6.70% | 13G (passive) | Jun 30, 2026 |
| Octagon Capital Advisors LP Joint filing with Octagon Investments Master Fund LP (5.70%), Ting Jia (5.70%) | 5,250,000 | 5.70% | 13G (passive) | Mar 31, 2026 |
| Soleus Capital Group, LLC Joint filing with Soleus Capital Master Fund, L.P. (5.20%), Soleus Capital, LLC (5.20%) and 3 more | 4,776,398 | 5.20% | 13G (passive) | Feb 2, 2026 |
| Dr. Jeffrey R. Jay, M.D. Joint filing with Great Point Partners, LLC (5.10%), Ms. Lillian Nordahl (5.10%) | 4,683,711 | 5.10% | 13G (passive) amendment | Dec 31, 2025 |
| Ms. Lillian Nordahl Joint filing with Great Point Partners, LLC (6.25%), Dr. Jeffrey R. Jay, M.D. (6.25%) | 4,683,711 | 6.25% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CNTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 7,419,355 | 8.08% | $4.11M | – | 0.06% |
| Nextech Invest, Ltd. | 7,419,355 | 8.08% | $4.11M | – | 0.20% |
| Soleus Capital Management, L.P. | 7,063,141 | 7.69% | $3.91M | +100,000 | 0.13% |
| BlackRock, Inc. | 6,169,250 | 6.71% | $3.42M | +5,322,554 | 0.00% |
| Avidity Partners Management LP | 4,998,267 | 5.44% | $2.77M | −4,998,267 | 0.44% |
| Franklin Resources Inc | 3,803,338 | 4.14% | $2.11M | – | 0.00% |
| Vanguard Capital Management LLC | 3,432,052 | 3.74% | $1.90M | +99 | 0.00% |
| Octagon Capital Advisors LP | 3,050,000 | 3.32% | $1.69M | −2,200,000 | 0.15% |
| Blue Owl Capital Holdings LP | 2,934,015 | 3.19% | $1.63M | −2,155,000 | 0.24% |
| TCG Crossover Management, LLC | 2,682,696 | 2.92% | $1.49M | – | 0.04% |
| Geode Capital Management, LLC | 1,830,309 | 1.99% | $1.01M | +1,226,542 | 0.00% |
| State Street Corp | 1,413,428 | 1.54% | $782.90K | +1,179,921 | 0.00% |
| Mpm Bioimpact LLC | 1,299,046 | 1.41% | $719.54K | −9,380,345 | 0.04% |
| Renaissance Technologies LLC | 1,041,399 | 1.13% | $576.83K | +858,400 | 0.00% |
| Acadian Asset Management LLC | 1,010,904 | 1.10% | $559.00K | New | 0.00% |
| ADAR1 Capital Management, LLC | 750,969 | 0.82% | $415.96K | +399,875 | 0.02% |
| Jane Street Group, LLC | 645,209 | 0.70% | $357.38K | +208,278 | 0.00% |
| Vanguard Portfolio Management LLC | 638,878 | 0.70% | $353.94K | New | 0.00% |
| Northern Trust Corp | 615,576 | 0.67% | $340.97K | +512,320 | 0.00% |
| Vanguard Fiduciary Trust Co | 433,888 | 0.47% | $240.37K | +92,544 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 79 | 63M | 68.4% | 36 / 19 | 13 / 15 | 14M | 31M |
| Q1 2026 | 59 | 79M | 86.2% | 25 / 10 | 13 / 7 | 29M | 11M |
| Q4 2025 | 43 | 65M | 71.1% | 10 / 8 | 8 / 4 | 6M | 10M |
| Q3 2025 | 37 | 69M | 75.1% | 6 / 6 | 7 / 7 | 2M | 2M |
| Q2 2025 | 39 | 69M | 74.7% | 4 / 9 | 9 / 7 | 1M | 3M |
| Q1 2025 | 42 | 71M | 77.7% | 3 / 6 | 14 / 12 | 9M | 3M |
| Q4 2024 | 52 | 73M | 79.2% | 14 / 15 | 12 / 4 | 21M | 5M |
| Q3 2024 | 42 | 57M | 61.7% | 15 / 6 | 11 / 6 | 5M | 7M |
| Q2 2024 | 34 | 59M | 64.2% | 19 / 8 | 3 / 9 | 56M | 1M |
| Q1 2024 | 25 | 4M | 4.3% | 4 / 6 | 2 / 3 | 0M | 0M |
| Q4 2023 | 24 | 4M | 3.9% | 2 / 7 | 1 / 1 | 1M | 0M |
| Q3 2023 | 23 | 3M | 2.8% | 3 / 7 | 1 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
39 funds held CNTX in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CNTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,815,486 | 3.06% | $1.56M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,329,496 | 2.54% | $1.29M | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 1,398,833 | 1.52% | $838.46K | 0.07% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 1,008,220 | 1.10% | $604.33K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 874,891 | 0.95% | $484.60K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 520,997 | 0.57% | $288.58K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 313,131 | 0.34% | $173.44K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 250,259 | 0.27% | $713.24K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 227,850 | 0.25% | $136.57K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 203,375 | 0.22% | $112.65K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 125,518 | 0.14% | $75.24K | 0.00% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 103,736 | 0.11% | $57.46K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 97,615 | 0.11% | $278.20K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Growth Index Fund | 88,395 | 0.10% | $48.96K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 72,616 | 0.08% | $206.96K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Martin A. Lehr | Chief Executive Officer, Director | 1,079,891 | 1.18% | Feb 23, 2026 |
| Alex C. Levit | Chief Legal Officer, Corp. Sec | 81,983 | 0.09% | Feb 23, 2026 |
| Jennifer Lynn Minai-Azary | Chief Financial Officer | 80,010 | 0.09% | Feb 23, 2026 |
| Karen Deborah Chagin | Chief Medical Officer | – | – | Feb 23, 2026 |
| Ullmann Claudio Dansky | Chief Medical Officer | – | – | Feb 14, 2025 |
| Andy Pasternak | Director | – | – | Jun 26, 2026 |
| Linda West | Director | – | – | Jun 26, 2026 |
| Karen L. Smith | Director | – | – | Jun 26, 2026 |
| Jennifer Evans Stacey | Director | – | – | Jun 26, 2026 |
| Philip W. Kantoff | Director | 3,533 | 0.00% | Jun 26, 2026 |
| Luke Nathaniel Walker | Director | – | – | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Martin A. Lehr Chief Executive Officer, Director | Jun 9, 2025 | Buy | +100,000 | $0.70 | $70.00K | 920,190 |
| Alex C. Levit Chief Legal Officer, Corp. Sec | Jun 6, 2025 | Buy | +20,000 | $0.58 | $11.60K | 29,000 |
| Jennifer Lynn Minai-Azary Chief Financial Officer | Jun 6, 2025 | Buy | +40,010 | $0.64 | $25.61K | 80,010 |
| Martin A. Lehr Chief Executive Officer, Director | Feb 21, 2023 | Buy | +5,823 | $0.84 | $4.89K | 159,701 |
| Martin A. Lehr Chief Executive Officer, Director | Feb 13, 2023 | Buy | +5,606 | $0.87 | $4.88K | 153,878 |
| Martin A. Lehr Chief Executive Officer, Director | Feb 6, 2023 | Buy | +5,040 | $0.97 | $4.89K | 148,272 |
| Martin A. Lehr Chief Executive Officer, Director | Jan 30, 2023 | Buy | +7,027 | $0.70 | $4.92K | 143,232 |
| Martin A. Lehr Chief Executive Officer, Director | Jan 23, 2023 | Buy | +6,839 | $0.72 | $4.92K | 136,205 |
| Martin A. Lehr Chief Executive Officer, Director | Jan 17, 2023 | Buy | +6,783 | $0.74 | $5.02K | 129,366 |
| Martin A. Lehr Chief Executive Officer, Director | Dec 16, 2022 | Buy | +20,000 | $0.74 | $14.80K | 122,583 |
| Jennifer Lynn Minai-Azary Chief Financial Officer | Dec 16, 2022 | Buy | +25,000 | $0.74 | $18.50K | 40,000 |
| Alex C. Levit Chief Legal Officer, Corp. Sec | Dec 9, 2022 | Buy | +6,000 | $0.85 | $5.10K | 9,000 |
| Martin A. Lehr Chief Executive Officer, Director | Aug 19, 2022 | Buy | +13,000 | $1.85 | $24.05K | 102,583 |
| Jennifer Lynn Minai-Azary Chief Financial Officer | Aug 17, 2022 | Buy | +15,000 | $1.80 | $27.00K | 15,000 |
| Tarek Sahmoud Chief Medical Officer | Aug 16, 2022 | Buy | +10,000 | $1.95 | $19.50K | 10,000 |
| Martin A. Lehr Chief Executive Officer, Director | Dec 16, 2021 | Buy | +13,000 | $3.22 | $41.86K | 820,190 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Exercise | +52,680 | $7.14 | $376.14K | 0 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +210,715 | – | – | 210,715 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Buy | +10,000 | $5.00 | $50.00K | 807,190 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +586,475 | – | – | 797,190 |
| Evan G. Dick SVP of R&D | Oct 22, 2021 | Conversion | +26,587 | – | – | 82,960 |
| Evan G. Dick SVP of R&D | Oct 22, 2021 | Conversion | +26,587 | – | – | 87,139 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +586,476 | – | – | 849,878 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Exercise | +52,680 | $7.14 | $376.14K | 52,680 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Buy | +10,000 | $5.00 | $50.00K | 99,583 |
| Martin A. Lehr Chief Executive Officer, Director | Oct 22, 2021 | Conversion | +210,722 | – | – | 263,402 |
| Alex C. Levit Chief Legal Officer, Corp. Sec | Oct 22, 2021 | Buy | +3,000 | $5.00 | $15.00K | 3,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Context Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 43,809 shares on Aug 25, 2026 over the last 90 days.
See a number that looks wrong?